The cost-effectiveness of requiring universal vs contextual self-injectable epinephrine autoinjector for allergen immunotherapy
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 123 (6) , 582-589
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Agency for Healthcare Quality and Research (5K08HS024599-02)
This publication has 23 references indexed in Scilit:
- Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapyAnnals of Allergy, Asthma & Immunology, 2016
- Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved?Current Treatment Options in Allergy, 2014
- Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitalsJournal of Allergy and Clinical Immunology, 2014
- Allergy Immunotherapy Adherence and Delivery Route: Location Does Not MatterThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Allergy immunotherapy: Reduced health care costs in adults and children with allergic rhinitisJournal of Allergy and Clinical Immunology, 2013
- A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapyInternational Forum of Allergy & Rhinology, 2012
- Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy–year 2Annals of Allergy, Asthma & Immunology, 2011
- Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrineAllergy and Asthma Proceedings, 2011
- Allergen immunotherapy: A practice parameter third updateJournal of Allergy and Clinical Immunology, 2011
- PROPHYLACTIC INOCULATION AGAINST HAY FEVERThe Lancet, 1911